Journal
LEUKEMIA
Volume 21, Issue 9, Pages 2010-2019Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.leu.2404849
Keywords
acute myeloid leukemia; growth; differentiation; cell cycle; stem cell; AML1-ETO9a
Categories
Funding
- NCI NIH HHS [CA104509] Funding Source: Medline
Ask authors/readers for more resources
The 8; 21 translocation is a common chromosomal abnormality in acute myeloid leukemia ( AML). We recently identified a naturally occurring leukemogenic splice variant, AML1- ETO9a ( acute myeloid leukemia- 1 transcription factor and the eighttwentyone corepressor- 9a), of t( 8; 21). To understand the leukemic potential of AML1- ETO9a, we performed microarray analysis with the murine multipotential hematopoietic FDCPmix A4 cell line. We identified changes in expression of various genes including CD44. CD44 is a type I transmembrane protein and functions as the major cellular adhesion molecule for hyaluronic acid, a component of the extracellular matrix. CD44 is expressed in most human cell types and is implicated in myeloid leukemia pathogenesis. We show that the presence of AML1- ETO9a significantly increased the expression of CD44 at both RNA and protein levels. Furthermore, the CD44 promoter is bound by AML1- ETO9a and AML1- ETO at the chromatin level. In addition, in the AML1- ETO9a leukemia mouse model CD44 is regulated in a cell context- dependent manner. Thus, our observations suggest that AML1- ETO and its splice variant AML1- ETO9a are able to regulate the expression of the CD44 gene, linking the 8; 21 translocation to the regulation of a cell adhesion molecule that is involved in the growth and maintenance of the AML blast/ stem cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available